Company intelligence / Profile preview

AltaThera Pharmaceuticals

Ownership: Private
Employees: ~320
Development stage: Commercial

Overview

AltaThera's first product, Sotalol IV, is a novel formulation of a widely used antiarrhythmic drug that shortens hospital stay by converting an inpatient procedure to an outpatient procedure.

Therapeutic areas: Cardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

sotalol

Commercial

Indications: Atrial fibrillation, Ventricular tachycardia

Partnerships

University of Utah

Beyond the preview

Go deeper on AltaThera Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AltaThera Pharmaceuticals.

Explore the full profile